PEGylated liposomal formulation of cromolyn have been developed with the purpose of improving the antitumor effects of cromolyn on human pancreatic adenocarcinoma cells. In stability study, the amount of protein adsorption on this PEGylated liposomes encapsulating cromolyn or gemcitabine was 4 fold lower compared to non-PEGylated liposome. In vitro, PEGylated liposomal cromolyn inhibited cell growth more effectively in BxPC-3 cells than Panc-1 cells, which indicate the high level of endogenous SI OOP in BxPC-3 cells and the lack of endogenous S100P in Panc-1 cells, and inhibited NF-kB activity in BxPC-3 compared with untreated group. Moreover, the combination of cromolyn with gemcitabine in PEGylated liposome demonstrated the strongest cytotoxicity to BxPC-3 pancreatic cancer cell, the powerful anti-tumor activity against BxPC-3 tumor bearing mice, as well as the highest apoptotic cells in tumor tissue. Thus, this formulation could provide a novel approach for treatment of pancreatic cancers.
展开▼
